Liminatus Pharma Stock Soars 92.76% on Regaining Nasdaq Compliance

On June 5, 2025, Liminatus Pharma's stock price surged by 92.76% in pre-market trading, marking a significant milestone for the company.

Liminatus Pharma's stock price soared to a record high after the company announced that it had regained compliance with Nasdaq listing standards. This development came after the company faced a notice for delayed filings, which had previously put its listing status at risk. The company received a notice of non-compliance from Nasdaq on May 29, 2025, due to the delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025. However, by June 3, 2025, Liminatus Pharma had filed the delayed report and regained compliance with Nasdaq's listing rules, effectively closing the matter.

This turnaround in compliance status has been met with enthusiasm from investors, who have responded positively to the company's efforts to address regulatory issues. The stock's surge reflects investor confidence in Liminatus Pharma's ability to navigate regulatory challenges and maintain its listing on a major exchange. The company's proactive approach to resolving compliance issues has likely contributed to the positive market sentiment surrounding its stock.